Statin Class Labeling Should Include Liver Failure As Adverse Event - OPDRA
Executive Summary
Class labeling for HMG-CoA reductase inhibitors should be updated to include liver failure as an adverse event, an Office of Postmarketing Drug Risk Assessment safety review concludes.